health
February 9, 2026
Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.
TL;DR
- Novo Nordisk is suing Hims & Hers for selling unapproved, compounded versions of its Wegovy obesity drugs.
- Novo alleges Hims' products are untested, put patients at risk, and infringe on patents.
- Hims plans to stop offering its copycat obesity pill after facing regulatory and legal threats.
- The lawsuit is part of a larger effort by Novo and Eli Lilly to combat compounded alternatives in the booming weight loss drug market.
- Hims argues the lawsuit is an attack on consumer access to personalized care and Big Pharma's attempt to limit choice.
- The FDA also plans legal action against Hims for its copycat pill.
- Novo has filed approximately 130 lawsuits regarding deceptive marketing and consumer fraud in the past two years.
Continue reading the original article